PubMed Health⌕ Search

Biomedical subjects

E Faragó

Publications and source records attributed to E Faragó.

At least 19 recordsLinked to original sources
PubMed2001

Molecular characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the line probe assay.

Two regions of rpoB associated with rifampin resistance were sequenced in 29 rifampin-resistant (determined by the proportion method) isolates of Mycobacterium tuberculosis obtained from patients from three counties in Hungary. Of the 29 resistant strains, 27 had a mutation in either the 81-bp region (26 strains) or the N-terminal region (1 strain), while the other 2 strains had no mutations in either region. The locations and frequencies of the mutations differed from those previously reported. The most common mutation in this study, D516V, was found in 38% of the Hungarian strains, a frequency 2 to 10 times higher than that found in studies from other countries. These same 29 isolates were also evaluated with the Inno-LiPA Rif. TB test (LiPA), a reverse hybridization assay for the rapid detection of rifampin resistance. Although LiPA detected the presence of an rpoB mutation in 26 of the resistant isolates, the type of mutation could not be determined in 4 isolates because the mutations present were not among those included on the LiPA strip. In addition, a silent mutation in one of the rifampin-susceptible control strains was interpreted as rifampin resistant by LiPA. These findings demonstrate the importance of validating this rapid molecular test by comparison with DNA sequence results in each geographic location before incorporating the test into routine diagnostic work.

Antitubercular Agents↗
PubMed2000

Ulcus vulvae acutum.

An acute vulvar ulcer was diagnosed based on a case history of a 17-year-old girl with genital ulcers. No relevant causative factors could be established. The gangrenous form of the disease, cutaneous anergy, and the cultured anaerobic pathogens suggested the possibility of an infectious pathogenesis.

Acute Disease↗
PubMed1989

Antibiotic treatment of patients with primary bronchial cancer.

In the course of the retrospective evaluation of the case histories of 198 patients with documented primary lung cancer, the authors analysed the respiratory tract infections described in the case records and observed during clinical treatment. The bacterial flora of the patients and the sensitivity of the pathogens to antibiotics were examined. A comparison was performed between the antibiotic treatment and infectious complications of patients undergoing a cytostatic regimen and of those who were not administered cytostatic agents. The analysis of the data of bronchial cancer patients led to the conclusion that an adequately chosen and performed antibiotic treatment results in lower mortality due to respiratory tract infections than is described in the literature.

Adenocarcinoma↗
PubMed1989

A study of plasma and cardiac tissue concentrations of ceftriaxone (Rocephin) in open heart surgery.

Postoperative infection following cardiac surgery procedures is a serious complication. Cephalosporines are frequently used in prophylaxis. The aim of this study was to determine whether adequate therapeutic concentrations of ceftriaxone were present in cardiac tissues and plasma after 2 g single dose administered intravenously. Twenty-four consecutive patients undergoing open heart surgical procedures enrolled in the study. The antibiotic concentration was measured by agar well diffusion method. Samples of plasma were taken simultaneously of tissue removal in order to determine the antibiotic penetration. Tissue concentrations in the cardiac appendage, in the mitral and aortic valves and in the vessels of the graft exceeded MIC of the anticipated pathogens and especially high concentration was detected in pericardiac tissue during the time of operation. Therapeutic level was achieved against only certain strains of Pseudomonas.

Cardiac Surgical Procedures↗
PubMed1988

Experience with brulamycin therapy in dialysed patients.

Forty-two patients with chronic renal insufficiency were subjected to Brulamycin therapy to combat complications such as sepsis, infection of the lower respiratory tract (bronchopneumonia) or of the urinary tract, Cimino fistula inflammation or peritonitis when the pathogenic agent was sensitive to nothing but aminoglycosides. The proper Brulamycin dose was selected under close clinical and laboratory control so as to fit the dialysed patient and his state of impaired renal function. The various forms of dialysis have been studied to determine their Brulamycin blood level diminishing effects. Familiarity with these effects is as important as with the patient's age, sex, body weight and actual state of renal function. The results confirm the experience gained by other authors that Brulamycin treatment--in curative non-toxic doses as indicated by the blood level index--is useful against severe infectious complications in anuric patients.

Adolescent↗
PubMed1988

Some questions of aminoglycoside therapy in the intensive care unit.

The pharmacokinetics of tobramycin and gentamycin was studied in patients of the intensive care unit. The "blood-bronchus barrier" was studied by determining the serum and sputum concentrations of the two drugs. At systemic administration, both aminoglycosides passed into the bronchial secretion and when they were inhaled, they appeared in the serum. By culturing the sputum samples of the patients of the intensive care unit, a high ratio of gram-negative pathogens was found. Bacteria were detected in some cases on the objects surrounding the patients, too.

Aminoglycosides↗
PubMed1988

A study of the levels of tobramycin and gentamicin in human serum and renal cortex and of changes in in vitro bacterial sensitivity.

Concentration of gentamicin and tobramycin in sera and renal tissue was determined. Though between the 2nd and 6th day of the treatment, gentamicin cumulated in the renal tissue, but it did not reach toxic value. Tobramycin did not show cumulation tendency. According to in vitro bacterium sensitivity studies, the wide scale use of tobramycin in the clinical practice caused the sudden increase of resistance. To avoid this, the rules of antibiotic treatment should be observed.

Adolescent↗
PubMed1983

Monitoring of the plasma concentration of a beta blocker with retarded effect (Slow Trasicor, 160 mg) in humans.

The plasma oxprenolol concentrations were measured in nine cases for 3 days following the application of 1 dragee (160 mg) daily of Slow Trasicor (CIBA). Blood sampling was carried out at the 1st, 6th, 12th, and 24th h during the 1st day, and at the 12th and 24th h during the 2nd and 3rd days, respectively. Oxprenolol reached a considerable plasma level already after the 1st h: 140 ng/ml on the average during the 1st day. The average concentrations were 284 and 202 at the 6th and 12th h, respectively. It decreased to 43 ng/ml by the 24th h. During the 2nd and 3rd days 124 and 122 ng/ml values were found at the 12th h, and 42 and 50 ng/ml at the 24th h. The results of these studies prove the good absorption of Slow Trasicor, as well as its prolonged presence in the plasma. The corresponding clinical improvements in the patients indicate the therapeutic effect of the plasma levels.

Delayed-Action Preparations↗
PubMed1981

Amoxycillin levels in human serum, bile, gallbladder, lung, and liver tissue.

Amoxycillin levels were measured in the serum, bile, lung, gallbladder, and liver tissue in 19 cases of lung and 22 cases of cholecyst operations following intramuscular administration of 1 g amoxycillin. After 60-160 min, 4.4-5.6 mcg/g intact lung tissue and 1.5-3.9 mcg/g tumorous lung tissue concentrations were found, representing 41-48% and 15-32%, respectively, of the corresponding serum levels. Between 70 and 160 min when the ducts cysticus was open, the cystic bile contained 5.2-8.8 mcg/ml, the bile taken from the biliary ducts showed 10.9-13.2 mcg/ml, whereas the wall of the gallbladder and the liver tissue displayed 4.4-5.1 and 1.7-2.8 mcg/g amoxycillin levels. These levels represented 50-92, 118-136, 50-52 and 17-28% of the actual serum levels. As in the serum levels, the bile and tissue levels were about twice as high as those following ampicillin administration. The amoxycillin levels measured in the serum, bile, and other tissue tissues in most cases exceeded the minimal inhibitory concentrations for most of the bacteria usually considered. Therefore, amoxycillin can be applied successfully to treat respiratory and biliary infections.

Adult↗
PubMed1980

Serum and lung tissue levels of fosfomycin in humans.

Fosfomycin levels were determined in the serum and the lung tissue removed during 26 pulmonary operations following intramuscular or intravenous administration of 2 g fosfomycin. In the serum the level was about 32 micrograms/ml 1--2 h subsequent to the administration. At the same time, the removed lung tissue showed 12--16 micrograms/g concentration in the apparently intact parts, amounting to 32--52% of the serum level, whereas in the tumorous lung tissue roughly half of this concentration was present. The fosfomycin levels found in the lung tissue are effective only against a group of bacteria causing respiratory inflammation.

Adult↗
PubMed1980

Data on sisomicin effect: human pharmacokinetic and bacteriological studies.

Antibiotic sensitivity of bacteria cultured from 1020 pulmonological, medical and surgical cases was determined. Inhibitory effect on the bacterial growth was observed most frequently with sisomicin among the antibiotics of aminoglycoside type. Sisomicin levels were studied in the serum and lung tissue in 20 cases of pulmonary operations. Fifty to ninety minutes subsequent to an intramuscular administration of 1 mg sisomicin per 1 kg body weight, the serum levels amounted to 4.0 mcg/ml, whereas the apparently healthy, the inflamed and tumourous parts of the removed lung tissue contained 2.2, 1.2 and 0.2 mcg/g. The serum level remained unchanged even after 110-150 min, when the lung tissue levels were 3.0, 1.5 and 2.1 mcg/g. The sisomicin concentrations found in the lung tissue are of bactericid effect only against a part of the bacteria studied. This fact emphasizes the importance of exact indication and use of doses of sisomicin.

Anti-Bacterial Agents↗
PubMed1980

Investigations on the flucloxacillin levels in human serum, lung tissue, pericardial fluid and heart tissue.

Following intramuscular administration of 500 mg flucloxacillin, the levels of this antibiotic were measured in the serum, lung, and heart tissue as well as pericardial fluid obtained during 24 lung and 19 heart operations. Between 55 and 160 min following administration, the intact, inflamed, and tumorous lung tissue pieces contained 3.3-4.0, 2.0-2.7, and 1.5-2.4 mcg/g flucloxacillin, respectively, representing 16-36, 13-16, and 10-18% of the actual serum levels. Pericardial fluid contained practically no flucloxacillin. The cardiac auricle contained 2.3-3.5 mcg/g between 35 and 130 min after administration; the mitral valve showed 1.1-2.5 mcg/g between 90 and 170 min afterward, whereas in the aortic valve 1.6 mcg/g was found between 105-220 min later. These concentrations represented 16-20, 7-22, and 12% of the actual serum levels. Both the serum and tissue levels proved to be higher than those of oxacillin at the same dosage. The flucloxacillin levels of the serum and tissues studied were much higher than the minimum inhibiting concentrations for the sensitive bacteria. Therefore, flucloxacillin is considered an excellent antibiotic for the treatment of respiratory infections and endocarditis, whereas its levels in the pericardial fluid show it insufficient for treatment of pericarditis.

Adult↗